APA (7th ed.) Citation

AM, V., MA, P., JF, C., S, N., D, M., A, E., . . . EM, O. (2025). Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival. Nature medicine, 31(2), 466. https://doi.org/10.1038/s41591-024-03362-3

Chicago Style (17th ed.) Citation

AM, Varghese, et al. "Clinicogenomic Landscape of Pancreatic Adenocarcinoma Identifies KRAS Mutant Dosage as Prognostic of Overall Survival." Nature Medicine 31, no. 2 (2025): 466. https://doi.org/10.1038/s41591-024-03362-3.

MLA (9th ed.) Citation

AM, Varghese, et al. "Clinicogenomic Landscape of Pancreatic Adenocarcinoma Identifies KRAS Mutant Dosage as Prognostic of Overall Survival." Nature Medicine, vol. 31, no. 2, 2025, p. 466, https://doi.org/10.1038/s41591-024-03362-3.